Table 1. Clinical outcome inputsa.
| Input | Unit | Current Scenario (GDMT) | New Scenario (GDMT + Empagliflozin) |
|---|---|---|---|
| Cardiovascular Death | events/100 patient-year | ||
| HFrEF without DM | 7.3% | 6.795% | |
| HFrEF with DM | 9.1% | 8.42% | |
| HF Hospitalisation | events/100 patient-year | ||
| HFrEF without DM | 12.35% | 9.235% | |
| HFrEF with DM | 18.62% | 12.36% | |
| Composite renal outcome | events/100 patient-year | ||
| HFrEF without DM | 2.05% | 0.955% | |
| HFrEF with DM | 4.17% | 2.3% | |
| Adverse Events | events/100 patient-year | ||
| Urinary Tract infection | 3.74% | 4.13% | |
| Genital mycotic infection | 0.54% | 1.38% |
aAnker et al [12]